There is a growing fear of potential fines and public relations nightmares due to the increasing demands of regulatory organizations (FDA and EMA) regarding post-market pharmacovigilance. Organizations struggle with trying to meet the increasing demands of both sets of regulations with their existing resources. Companies have had to restructure, create entirely new databases, adjust their departments, allocate funds, and increase employees’ workloads. In fact, many companies are struggling on how to approach these regulations successfully especially when it comes to the EMA laws.
Delegates at the marcus evans 3rd Pharmacovigilance, Risk Management, & Adverse Event Reporting Conference will learn and discuss how leaders in the industry are addressing challenges regarding global pharmacovigilance and benefit risk analysis. Hot topics will include the impact of the new EMA pharmacovigilance regulations, AER, signal detection, and benefit risk management. Delegates will have the unique opportunity to meet with their contemporaries to discuss the future of drug safety in post marketing.
Attending this premier marcus evans conference will enable you to:
Industry leaders attending this conference will benefit from a dynamic presentation format consisting of workshops, panel discussions, and case studies. Attendees will experience highly interactive conference sessions, 10-15 minutes of Q&A time after each presentation, 4+ hours of networking, and exclusive online access to materials post-event.
Hear what previous attendees from our Pharmacovigilance Conference Series have to say:
“Great in-depth coverage of hot topics in an intimate setting that lent itself to excellent discussions.” –Novartis
“One of the best meetings I’ve attended. Excellent organization, topics, and speakers. Overall well done.” –Sanofi-Aventis
“Relevant and useful topics from industry perspective.” - Abbott